Search

everythinglearnresearchcommunity

for

Search:↓

A 27-year-old male experienced significant hair regrowth using 0.5 mg Dutasteride and 2.5 mg Oral Minoxidil daily, with minimal side effects. He noticed improvement in hairline and crown after an initial shedding phase, and he did not use Finasteride prior to this treatment.

A man shared his 6.5-month progress using finasteride, a derma roller, and biotin supplements for hair loss, with no side effects and overcoming two shedding phases. Commenters are impressed, noting hairline improvement and discussing the potential of these treatments in regrowing hair, especially at the temples.

PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.

The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

User shares link to conference about Pyrilutamide. Discussion includes phase 2 results, company's plans, and upcoming phase 3 trial.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

A user shared their 6.5-month experience with topical finasteride (2%) and minoxidil (5%), noting initial progress followed by a significant shedding phase. Others in the conversation reassured that shedding is normal and suggested staying consistent with the treatment for potential regrowth.

Dutasteride can take 6 months to 2 years to show results, and patience is needed during the shedding phase. Some users suggest adding RU58841 to help maintain existing hair.

The user is experiencing hair loss and is using 2% ketoconazole shampoo, Minoxidil, and Finasteride. They are considering switching from Finasteride to Dutasteride, but others suggest waiting due to a possible shedding phase.

A user shared their 9-month hair regrowth progress using 2 mg of oral Minoxidil, topical Finasteride, and dermarolling. They experienced shedding phases but saw improvement, especially in the front and widow's peak areas.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

Pyrilutamide, a potential hair loss treatment that has been tested in Phase 2 trials and may be available for purchase through a group buy in June. It is purported to have similar effects on hair growth as Dutasteride.

The user shared a 10-month hairline update using 5% topical Minoxidil and 2.5% oral Finasteride, noting some improvement despite a second shedding phase. They switched to oral Minoxidil for convenience, which may have caused the shedding.

A user shared their experience with hair recovery after a second shedding phase while using Finasteride. They advise staying consistent with treatment, as it can take 1-2 years or more to see results, and also mention using Ketoconazole but are unsure of its effectiveness.

The user switched from finasteride to dutasteride, taking 0.5 mg oral dutasteride and 2.5 mg oral minoxidil daily, and reported significant hair regrowth with no side effects. The user experienced a shedding phase lasting a bit over a month after switching to dutasteride.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

The user shared their 3-month progress using 5% topical minoxidil and microneedling with a 1mm dermaroller, noting significant hair growth without using finasteride. They applied minoxidil twice daily and used the dermaroller three times a week, experiencing a short shedding phase after 2-3 weeks.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

The user has been using finasteride for 16 months, minoxidil for 11 months, and started microneedling 2 months ago, experiencing shedding phases. They are questioning whether they are experiencing miniaturization or regrowth.

The user has been using Finasteride for hair loss and is considering adding alphatradiol, stemoxydine, or 2% minoxidil to their regimen. They are concerned that stemoxydine, which shortens the resting phase of hair, might accelerate hair loss in those not using Finasteride by depleting hair cycles without strengthening miniaturized hairs.

After 3 months of using oral minoxidil and finasteride, the user experienced thicker hair and filled-in thinning areas, with no major side effects except an initial shedding phase. The treatments were prescribed online, and the user noticed results after 2.5 months.

The user shared their hair loss journey, using 0.5mg finasteride, topical minoxidil, and dermarolling initially, then increasing to 1mg finasteride and adding 2.5mg oral minoxidil. They experienced significant regrowth but are currently facing a prolonged shedding phase, hoping for stabilization and regrowth.

The user shared progress pictures after using topical dutasteride for 4 months, experiencing heavy shedding at month 2, which returned to baseline 1.5 months ago. Previous treatments with topical and oral finasteride and minoxidil were ineffective or caused side effects, and the user is hopeful about the shedding phase indicating potential effectiveness of topical dutasteride.

The user has experienced noticeable hair regrowth after 3 months using minoxidil daily, finasteride every other day, a derma stamp 2-3 times a week, and 2% Ketoconazole shampoo. They adjusted finasteride usage due to decreased libido and are nearing the end of the shedding phase.

The user started hair loss treatment on June 26th using 1.25mg finasteride, 1ml 5% minoxidil twice a day, derma rolling every 1.5 weeks, and 2% ketoconazole foam twice a week. They experienced significant hair growth in the first four months, with thicker hair and improved hairline, but had a rough shedding phase in November.

Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).